Physiopathology of prolactin secretion in obesity

International Journal of Obesity

Volumn 24, Issue , 2000, Pages S104-S108

  Kopelman, P G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

HPA; Hypothalamus; Insulin; Leptin; Pituitary

Indexed keywords

DOPAMINE; ESTROGEN; GLUCOCORTICOID; GLUCOSE; INSULIN; PROLACTIN; PROTIRELIN;

BODY WEIGHT; CONFERENCE PAPER; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; LIPID STORAGE; NEUROENDOCRINE SYSTEM; OBESITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE;

ADRENAL GLANDS; BODY WEIGHT; HUMANS; HYPOTHALAMUS; LEPTIN; OBESITY; PITUITARY GLAND; PROLACTIN; THYROTROPIN-RELEASING HORMONE;

EID: 0033928131     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801291     Document Type: Article

References (31)

1. Cooke NE. Prolactin: basic physiology. In: Degroot LJ, Besser M, Burger HG, Jameson IL et al (eds). Endocrinology. WB Saunders: Philadelphia, PA, 1995, pp 368-393.
2. Kelly PA, Djiane J, Postel-Vinay V-C, Edery M. The prolac-tin/growth hormone receptor family. Endocr Rev 1991; 12: 235-251.
3. Casabiell X, Robertson MC, Friesen HG, Casanueva FF. Cleaved prolactin and its 16 K fragment are generated by an acid protease. Endocrinology 1989; 125: 1967-1972.
4. Markoff E, Sigel MB, Lacour N et al. Glycosylation selectively alters the biological activity of prolactin. Endocrinology 1988; 123: 1303-1306.
5. Sassin JF, Frantz AG, Kapen S, Weitzman ED. The nocturnal rise of human prolactin is dependent on sleep. J Clin Endocr Metab 1973; 37: 436-440.
6. Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocr Metab 1972; 35: 840-851.
7. Pontiroli AE, Baio G, Stella L et al. Effects of naloxone on prolactin, luteinizing hormone and cortisol responses to surgical stress in humans. J Clin Endocr Metab 1982; 55: 378-380.
8. LeBlanc H, Lachelin GCL, Abu-Fadil S, Yen SSC. Efects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocr Metab 1976; 43: 668-674.
9. Noel GL, Dimond RC, Wartofsky L et al. Studies of prolactin and TSH secretion by continuous infusion of small amounts of thyrotropin releasing hormone (TRH). J Clin Endocr Metab 1974; 39: 6-17.
10. Said SI, Porter JC. Vasoactive intestinal polypeptide: Release into hypophyseal portal blood. Life Sci 1979; 24: 227-230.
11. Pilotte NS, Porter JC. Dopamine in hypophysial portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine. Endocrinology 1981; 108: 2137-2141.
12. Meier AH. Temporal synergism of corticosterone and prolactin controlling seasonal conditions in the white throated sparrow, Zonotrichia albicollis. In: Scheving LE, Halberg G, Panley JE (eds). Chronobiology Igaku Schoi: Tokyo, 1974, pp 647-651.
13. Cincotta AH, Wilson JM, deSouza CJ, Meier AH. Properly timed injections of cortisol and prolactin produce long-term reductions in obesity, hyperinsulinaemia and insulin resistance in the Syrian hamster (Mesocricetus auratus). J Endocr 1989; 120: 385-391.
14. Guyda HJ, Friesen HG. Serum prolactin levels in humans from birth to adult life. Pediat Res 1973; 7: 534-540.
15. Copinschi G, Dehaet MH, Brian JP et al. Simultaneous study of cortisol, growth hormone and prolactin nycthemeral variations in normal and obese subjects. Influence of prolonged fasting in obesity. Clin Endocr 1978; 9: 15-23.
16. Kopelman PG, Pilkington TRE, White N, Jeffcoate SL. Impaired hypothalamic control of prolactin secretion in massive obesity. Lancet 1979; i: 747-749.
17. Kopelman PG, Pilkington TRE, Wite N, Jeffcoate SL. Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. Br Med J 1980; 281: 358-359.
18. AvRuskin TW, Pillai S, Kasi K et al. Decreased prolactin secretion in childhood obesity. JPaediat 1985; 106: 373-378.
19. Jung RT, Campbell RG, James WPT, Callingham BA. Altered hypothalamic sympathetic responses to hypoglycaemia in familial obesity. Lancet 1982; i: 1043-1046.
20. Donders SHJ, Pieters GF, Heeval JG et al. Disparity of thyrotrophin (TSH) and prolactin responses to TSH-releasing hormone in obesity. J Clin Endocr Metab 1985; 61: 56-59.
21. Lala VR, Ray A, Jamias P, Orteza N, Fiscina B, Noto R. Prolactin and thyroid status in prepubertal children with mild to moderate obesity. J Am Coll Nutr 1988; 7: 361-366.
22. Sowers JR, McCuallum RW, Hersham JM et al. Comparison of metoclopramide with other dynamic tests of prolactin secretion. J Clin Endocr Metab 1976; 43: 679-691.
23. Laduron P, Leysen J. Domperidone a specific in vitro dopamine-antagonist devoid of in vivo central dopaminergic activity. Biochem Pharmac 1979; 28: 2161-2167.
24. Kopelman PG, Finer N, White N et al. Impaired hypothalamic control of prolactin secretion in obesity. J Obes Weight Regul 1983; 2: 172-180.
25. Argenio G, Bernini G, Vivaldi MS, Del Corso C et al. Effect of fenfluramine on prolactin and thyroid-stimulating-hormone response to thyrotropin-releasing hormone in obese and normal women. Eur J Clin Pharmac 1990; 39: 13-16.
26. Altomonte L, Zoli A, Alessi F, Ghirlanda G, Manna R, Greco AV. Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects. Horm Res 1987; 27: 190-194.
27. Argenio GF, Bernini GP, Vivaldi MS, del Corso C, Santoni R, Franchi F. Naloxone does not modify fenfluramine-induced prolactin increase in obese patients. Clin Endocr 1991; 35: 505-508.
28. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalisation of prolactin levels. Clin Endocr 1998; 48: 447-453.
29. Weaver JU, Noonan K, Kopelman PG. An association between hypothalamic-pituitary dysfunction and peripheral endocrine function in obesity. Clin Endocr 1991; 35: 97-102.
30. Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor gene. Mol Psychiat 1996; 1: 325-335.
31. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995; 5: 121-141.